Lutetium Lu 177 AB-3PRGD2

{
  "id": "MLC-T-ONC-014908",
  "term": "Lutetium Lu 177 AB-3PRGD2",
  "field": "Oncology and biomedicine",
  "definition": "A radiopharmaceutical agent comprised of a pegylated cyclic arginine-glycine-aspartic acid (RGD) dimer (PRGD2) labeled with lutetium Lu 177, with potential antineoplastic activity against alphaVbeta3 integrin-expressing tumor cells. Upon administration of lutetium Lu 177 AB-3PRGD2, the RGD moiety binds to alphaVbeta3 integrin on alphaVbeta3 integrin-expressing tumor cells. The tumor cells can be eradicated upon direct cytotoxicity through beta radiation. AlphaVbeta3 integrin, a member of the integrin receptor family, is overexpressed on certain tumor cells and tumor endothelial cells while minimally or not expressed on healthy, normal cells; this receptor plays a key role in angiogenesis, tumor proliferation and survival.",
  "synonyms": [
    "177Lu-AB-3PRGD2",
    "177Lu-3PRGD2"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/lutetium-lu-177-ab-3prgd2/"
}